Djati Susilo, - and Sony Wibisono, - and Usman Hadi, - (2020) TSH, FT4, and CD4 Profile in HIV/AIDS Patients Before and After Antiretroviral Fixed-Dose Combination Tenofovir, Lamivudine, Evafirenz Therapy. Systematic Reviewes in Pharmacy, 11 (3). pp. 635-639. ISSN 0975-8453

	Text (Artikel) C10 Artikel.pdf Download (7MB)
	Text (Similarity) C10 Similarity.pdf Download (1MB)
	Text (Peer Review) C10 Peer Review.pdf Download (2MB)

Abstract

HIV infection can cause thyroid abnormality, and the use of Antiretroviral (ARV) can make it worse. The objective of this study was to identify the difference of thyroid profile level in HIV/AIDS before and after fixed-dose combination (FDC) therapy. This was a descriptive longitudinal observational study using one group pretest and posttest comparative design involving 20 samples. The subjects were all HIV/AIDS patients receiving ARV FDC but never received such therapy before. The mean age of the subjects was 32.9±9.19 years, with a range of 20-50 years. The majority of the subjects were males 15 (75%) and the most risk factor was vaginal sex as much as 11 subjects (55%). TSH and FT4 mean levels before therapy were 1.1±0.22 µIU/ml FT4 and 1.15±0.17 ng/dl, respectively and after receiving FDC ARV were of 2.34±1.23 µIU/ml and 1.01 ± 0.14 ng/dl, respectively. There were significant differences in TSH (p = 0.000), FT4 (p = 0.012), and CD4 (p = 0.000) in HIV/AIDS patients before and after receiving FDC ARV for 3 months. There was a significant difference in thyroid profile before and 3 months after received ARV FDC.

Actions (login required)

View Item